ArticleClinical and translational radiation oncology2018

Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide.

Marco C Merlano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.